Therapeutic Advances in Medical Oncology · 2020 · 19 citations · 28 references
MedicineHematologyOncologyChemotherapyHematologic OncologyMedical OncologyAnemiaChemotherapy In Hematologic MalignanciesHematologic Malignancy TherapyIron Chelation TherapyIron DeficiencyIron Deficiency DisordersC-reactive Protein TestingErythropoiesis-stimulating Agent UseErythropoiesis-stimulating TherapyFerritin StatusHepcidin ExpressionIntravenous Iron AdministrationIron Deficiency TreatmentSerum Ferritin Assessment
Background: Anemia is commonly encountered in cancer patients receiving active chemotherapy. Due to adverse events and presumed negative effects on disease-progression and survival, erythropoiesis-stimulating agents are not frequently used. In this study, we assess the efficacy and safety of intravenous ferric carboxymaltose (FCM) to treat cancer-induced anemia (CIA). Patients and Methods: We recruited adult cancer patients on active chemotherapy with a hemoglobin (Hb) level ⩽11.0 g/dL. Based on serum ferritin (sFr) and transferrin saturation (TSAT), patients were divided into 3 groups: group I (absolute iron deficiency, n = 26) with sFr < 30 ng/mL and TSAT < 20%; group II (functional iron deficiency, n = 24) with sFr 30–800 ng/mL and TSAT < 20%; and patients with TSAT ⩾ 20% were placed in group III as “others” ( n = 34). All patients were treated with intravenous FCM. Serum hepcidin and C-reactive protein were used as biomarkers to predict response. Results: A total of 84 patients with a median age (SD) of 53.8 (10.6) were recruited. Baseline median Hb level was 10.2 (range: 8.3–11.0) gm/dL. At week 12, there was a significant increment in Hb level for patients in groups I and II (median increment: 2.35 and 1.5 gm/dL, respectively), with limited response observed in group III, and most of the increment noted as early as week 3 (⩾1.0 g/dL). Responders tended to have lower levels of hepcidin. No clinically significant adverse events were reported; however, asymptomatic hypophosphatemia was observed in 39 (46.4%) patients. Conclusions: Intravenous FCM is a safe and effective treatment option for the management of a subgroup of patients with CIA. The study was registered at ClinicalTrials.gov [Identifier: NCT04246021]
28
Timothy J. Littlewood, Emilio Bajetta, J.W.R. Nortier et al. · Journal of Clinical Oncology · 2001 · 977 citations
Medicine, Hematology, Pharmacology +13
Heinz Ludwig, Simon Van Belle, Peter Barrett‐Lee et al. · European Journal of Cancer · 2004 · 928 citations
Medicine, Hematology, Oncology +10
Brian Leyland‐Jones, Marek Pawlicki, Tadeusz Pieńkowski et al. · Journal of Clinical Oncology · 2005 · 665 citations · Full text
Medicine, Oncology, Pharmacology +15
Janice Gabrilove, Charles S. Cleeland, Robert B. Livingston et al. · Journal of Clinical Oncology · 2001 · 596 citations
Medicine, Hematology, Pharmacology +14